ClinicalTrials.gg
CompletedNCT01947153Updated Feb 25, 2015Results posted

Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.

A Phase 1 interventional study of Metformin and Linagliptin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-25.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The objective of the current study is to demonstrate bioequivalence of two 2.5 mg linagliptin/500 mg metformin fixed dose combination tablets compared to the free combination of the linagliptin 5 mg and metformin 1000 mg in healthy male and female volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated written prior to admission to the study in accordance with Good Clinical Practice and the local legislation
  • Healthy males and females according to the following criteria:

Based upon a complete medical history, including physical examination, vital signs (BP, PR), 12-lead and clinical laboratory tests (haematology, clinical chemistry and urinalysis).

  • Age 18 to 45 years (incl.)
  • by Quetelet between 18.50 to 24.99 kg/m2 (incl.)
  • Female subjects of who agree on using double-barrier during the study. If a female is (no menses for at least 2 years) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) she will be exempt from the requirement. In case of using oral contraceptives, these should be withdrawn at least 2 months before the first drug dosing.
  • Male subjects who agree on using effective contraception during the study (barrier contraceptive methods)

Exclusion criteria

Exclusion criteria:

  • Any finding of the medical examination (including BP, PR and ) deviating from normal and of clinical relevance
  • Any laboratory value outside the reference range that is of clinical relevance
  • Any evidence of a concomitant disease
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Positive results of blood tests for infections (, syphilis, or C)
  • A positive urine drug screening test at screening and on admission to the trial site in each treatment period.
  • A positive alcohol breath test at screening and on admission to the trial site in each treatment period.
  • Surgery of the gastrointestinal tract (except appendectomy)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Fixed dose combination

    Linagliptin/Metformin

    Drug: Linagliptin · Drug: Metformin

  • Experimental
    Free combination

    Linagliptin and Metformin

    Drug: Metformin · Drug: Linagliptin

Interventions

06

What researchers measure

Primary outcomes

  1. Linagliptin: AUC 0-72 (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 72 Hours)

    Linagliptin: AUC 0-72 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 hours)

    Time frame: 2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

  2. Metformin: AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)

    Metformin: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)

    Time frame: 2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

  3. Linagliptin: Cmax (Maximum Measured Concentration of the Analyte in Plasma)

    Linagliptin: Cmax (maximum measured concentration of the analyte in plasma)

    Time frame: 2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

  4. Metformin: Cmax (Maximum Measured Concentration of the Analyte in Plasma)

    Metformin: Cmax (maximum measured concentration of the analyte in plasma)

    Time frame: 2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

Secondary outcomes

  1. Linagliptin: AUC 0-inf (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity)

    Linagliptin: AUC 0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

    Time frame: 2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

  2. Metformin: AUC 0-inf (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity)

    Metformin: AUC 0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

    Time frame: 2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

  3. Linagliptin: AUC 0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)

    Linagliptin: AUC 0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)

    Time frame: 2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

07

Results

Posted Feb 25, 2015

Participant flow

Test Period 1
Participant flow — Test Period 1
MilestoneFixed Dose Combination First, Then Free CombinationFree Combination First, Then Fixed Dose Combination
Started1818
Completed1818
Not completed00
Test Period 2
Participant flow — Test Period 2
MilestoneFixed Dose Combination First, Then Free CombinationFree Combination First, Then Fixed Dose Combination
Started1818
Completed1818
Not completed00

Outcome measures

PrimaryLinagliptin: AUC 0-72 (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 72 Hours)

Linagliptin: AUC 0-72 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 hours)

Time frame:
2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Linagliptin: AUC 0-72 (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 72 Hours)
nmol*h/LFixed Dose CombinationFree Combination
Linagliptin: AUC 0-72 (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 72 Hours)293 ± 23.4288 ± 22.9
Statistical analysis
  • Fixed Dose Combination vs Free Combination · ANOVA · p = <0.0001 (The p-value relates to the null hypothesis of non-equivalence.) · Geometric mean ratio: 102.92 · 90% CI 98.370 to 107.688The geometric mean ratio is calculated as the geometric mean of 'Fixed dose combination' divided by the geometric mean of 'Free combination '.
PrimaryMetformin: AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)

Metformin: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)

Time frame:
2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · ng*h/mL
Metformin: AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)
ng*h/mLFixed Dose CombinationFree Combination
Metformin: AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)13000 ± 27.312100 ± 24.2
Statistical analysis
  • Fixed Dose Combination vs Free Combination · ANOVA · p = <0.0001 (The p-value relates to the null hypothesis of non-equivalence.) · Geometric mean ratio: 105.14 · 90% CI 99.645 to 110.941The geometric mean ratio is calculated as the geometric mean of 'Fixed dose combination' divided by the geometric mean of 'Free combination '.
PrimaryLinagliptin: Cmax (Maximum Measured Concentration of the Analyte in Plasma)

Linagliptin: Cmax (maximum measured concentration of the analyte in plasma)

Time frame:
2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · nmol/L
Linagliptin: Cmax (Maximum Measured Concentration of the Analyte in Plasma)
nmol/LFixed Dose CombinationFree Combination
Linagliptin: Cmax (Maximum Measured Concentration of the Analyte in Plasma)10.3 ± 36.49.57 ± 36.2
Statistical analysis
  • Fixed Dose Combination vs Free Combination · ANOVA · p = 0.0014 (The p-value relates to the null hypothesis of non-equivalence.) · Geometric mean ratio: 109.05 · 90% CI 98.299 to 120.968The geometric mean ratio is calculated as the geometric mean of 'Fixed dose combination' divided by the geometric mean of 'Free combination '.
PrimaryMetformin: Cmax (Maximum Measured Concentration of the Analyte in Plasma)

Metformin: Cmax (maximum measured concentration of the analyte in plasma)

Time frame:
2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · ng/mL
Metformin: Cmax (Maximum Measured Concentration of the Analyte in Plasma)
ng/mLFixed Dose CombinationFree Combination
Metformin: Cmax (Maximum Measured Concentration of the Analyte in Plasma)1840 ± 28.21700 ± 27.0
Statistical analysis
  • Fixed Dose Combination vs Free Combination · ANOVA · p = <0.0001 (The p-value relates to the null hypothesis of non-equivalence.) · Geometric mean ratio: 105.81 · 90% CI 98.471 to 113.692The geometric mean ratio is calculated as the geometric mean of 'Fixed dose combination' divided by the geometric mean of 'Free combination '.
SecondaryLinagliptin: AUC 0-inf (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity)

Linagliptin: AUC 0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

Time frame:
2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Linagliptin: AUC 0-inf (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity)
nmol*h/LFixed Dose CombinationFree Combination
Linagliptin: AUC 0-inf (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity)467 ± 25.8479 ± 29.5
Statistical analysis
  • Fixed Dose Combination vs Free Combination · ANOVA · p = <0.0001 (The p-value relates to the null hypothesis of non-equivalence.) · Geometric mean ratio: 98.48 · 90% CI 92.177 to 105.208The geometric mean ratio is calculated as the geometric mean of 'Fixed dose combination' divided by the geometric mean of 'Free combination '.
SecondaryMetformin: AUC 0-inf (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity)

Metformin: AUC 0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

Time frame:
2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · ng*h/mL
Metformin: AUC 0-inf (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity)
ng*h/mLFixed Dose CombinationFree Combination
Metformin: AUC 0-inf (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity)13400 ± 26.812500 ± 24.1
Statistical analysis
  • Fixed Dose Combination vs Free Combination · ANOVA · p = <0.0001 (The p-value relates to the null hypothesis of non-equivalence.) · Geometric mean ratio: 104.62 · 90% CI 99.274 to 110.254The geometric mean ratio is calculated as the geometric mean of 'Fixed dose combination' divided by the geometric mean of 'Free combination '.
SecondaryLinagliptin: AUC 0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)

Linagliptin: AUC 0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)

Time frame:
2 hours (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · nmol*h/L
Linagliptin: AUC 0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)
nmol*h/LFixed Dose CombinationFree Combination
Linagliptin: AUC 0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point)293 ± 23.4288 ± 22.9
Statistical analysis
  • Fixed Dose Combination vs Free Combination · ANOVA · p = <0.0001 (The p-value relates to the null hypothesis of non-equivalence.) · Geometric mean ratio: 102.92 · 90% CI 98.370 to 107.688The geometric mean ratio is calculated as the geometric mean of 'Fixed dose combination' divided by the geometric mean of 'Free combination '.

Adverse events

Collected over From first study drug administration until 30±2 days after the last study drug administration. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fixed Dose Combination—0/36 (0%)1/36 (2.8%)
Free Combination—0/36 (0%)4/36 (11.1%)
Most frequent other events
Most frequent other events
EventFixed Dose CombinationFree Combination
HeadacheNervous system disorders1/364/36

Baseline characteristics

Treated set (TS): includes all subjects who had been dispensed study medication and were documented to have taken at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)All Subjects
Mean25.0 ± 6.2
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female20
Male16
08

Study locations

1 site
  • 1288.21.1 Boehringer Ingelheim Investigational Site
    St. Petersburg, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2013
First posted
Sep 20, 2013
Start
Nov 2013
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results first posted
Feb 25, 2015
Last update
Feb 25, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01947153
Responsible party
Sponsor
First posted
Sep 20, 2013
Start date
Nov 2013
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Feb 25, 2015
Last update
Feb 25, 2015

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Linagliptin

Start the discussion